{"id":"NCT03062358","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)","officialTitle":"A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-27","primaryCompletion":"2021-06-30","completion":"2024-10-15","firstPosted":"2017-02-23","resultsPosted":"2023-03-21","lastUpdate":"2024-11-05"},"enrollment":453,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"BIOLOGICAL","name":"pembrolizumab","otherNames":["KEYTRUDAÂ®"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"OTHER","name":"best supportive care (BSC)","otherNames":[]}],"arms":[{"label":"pembrolizumab + BSC","type":"EXPERIMENTAL"},{"label":"placebo + BSC","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC). The primary hypothesis of this study is that overall survival is prolonged in participants who receive pembrolizumab compared to those who receive placebo.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 4 years","effectByArm":[{"arm":"Pembrolizumab + BSC","deltaMin":14.6,"sd":null},{"arm":"Placebo + BSC","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0180"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":24},"locations":{"siteCount":41,"countries":["China","Hong Kong","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":["36455168","40486134"],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":76,"n":299},"commonTop":["Aspartate aminotransferase increased","Alanine aminotransferase increased","Blood bilirubin increased","Platelet count decreased","Gamma-glutamyltransferase increased"]}}